Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369603 · ClinicalTrials.gov registry record · Phase 4
Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT00369603 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 4 participants.
The verdict
NCT00369603, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether standard medications approved for Alzheimer's disease treatment differ in their action on brain functioning and whether any observed brain activity differences as result of treatment are associated with particular patterns of dementia improvement or reduced decline.
Interventions
- DRUG Aricept
- DRUG Razadyne ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369603
The ClinicalTrials.gov registry entry for NCT00369603 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aricept is the first listed.
NCT00369603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369603 about?
NCT00369603 is a clinical study titled "Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients". The purpose of this study is to determine whether standard medications approved for Alzheimer's disease treatment differ in their action on brain functioning and whether any observed brain activity differences as result of treatment are associated with particular patterns of dementia improvement or ...
What is the current status of trial NCT00369603?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00369603?
The interventions under investigation include: Aricept (DRUG), Razadyne ER (DRUG).
Who is sponsoring clinical trial NCT00369603?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.